For the six months ended December 31, 2004, the
gross profit increased to $1,730,000 or 32% compared to $1,391,000 or 30% for
the first six months of the prior year.08 per basic and diluted share as
compared to $2,462,000 or $0.

Kevin Simpson, President and Chief Operating Officer stated, "Last
quarter, we indicated that the planned increase in spending is necessary to
complete the development and launch of the new disposable products needed to
take the Company to the next level of revenues, gross margin and ultimately,
profitability. The Company anticipates market launch of the TPD in Europe in the
fourth quarter of fiscal 2005. The Company's technology platforms lead the world in their
ability to produce biological products from single units of blood. Chapman, Ph .
Chapman will be responsible for coordinating the life science and clinical
activities with the R+D, clinical affairs, global medical and marketing teams,
and field sales and service to facilitate the successful development, launch
and promotion of new and existing medical device products.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to , certain delays
beyond the company's control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission.

readable mazur

For the six months ended December 31,
2004, the net loss was $3,720,000 or $0. ThermoGenesis Corp.

THERMOGENESIS Hires New Executive Director of Scientific Affairs

THERMOGENESIS CORP.

umbilical vial

-- To employ outside advisors and absorb increased audit fees in
connection with Sarbanes-Oxley Section 404 compliance .
Included in the blood processing set is a patented 25 ml freezing bag suitable
for long term storage in the -196 C liquid nitrogen of the (R) System.

cynwyd tissues

The System allows up to six units to be processed simultaneously.

Company Conference Call
Management will host a conference call today , February 9, 2005 at 11:00 am
PST to review the financial results and other corporate events, followed by a
Q+A session. A replay of the
conference call will be available two hours after the call for the following
five business days by dialing: 877-344-7529 within the U., THERMOGENESIS
CORP . (Nasdaq: KOOL) announced today that it has hired John R.

germplasm thermodynamics

Condensed Statements of Operations
(Unaudited)

Three Months Ended Six Months Ended
December 31, December 31,
2004 2003 2004 2003

Net revenues $2,954,000 $2,500,000 $5,351,000 $4,643,000

Cost of revenues 2,004,000 1,698,000 3,621,000 3,252,000

Gross profit 950,000 802,000 1,730,000 1,391,000

Expenses:

Selling, general and
administrative 1,452,000 1,285,000 2,886,000 2,421,000

Research and
development 1,395,000 748,000 2,664,000 1,447,000

Total operating
expenses 2,847,000 2,033,000 5,550,000 3,868,000

Interest and other
income, net 56,000 8,000 100,000 15,000

Net loss ($1,841,000) ($1,223,000) ($3,720,000) ($2,462,000)

Basic and diluted net
loss per common share ($0. Most
recently, he held the position of Sr. At Baxter,
he provided the scientific leadership in creating the CE mark and market
launch of a new pathogen inactivation system of fresh frozen plasma using
photoactivation of methylene blue .

cynwyd freezing

04 per basic and diluted common share
compared to $1,223,000 or $0.04) ($0.
as its Executive Director of Scientific Affairs.

kuopio freezing

5 ml of
autologous thrombin from approximately 11 ml of patient plasma for various
applications, including topical hemostasis or release of growth factors from
platelets. Patents and authored 32 scientific publications in
the fields of blood processing , biologics, devices and chemistry."
Kevin Simpson, President + COO, noted that "Dr.

In this section we also include companies which research and store frozen tissue for transplant and other uses.

vial immortality

Record Q2 Revenues and Gross Margin Increase 18% Over Prior Year - Company
Makes Key Investments in New Product Development, Clinical Trials + Compliance
With Section 404 of the Sarbanes -Oxley Act of 2002

RANCHO CORDOVA, Calif. Net revenues for the quarter ended December 31 , 2004 increased 18% to a
second quarter record of $2,954,000, compared to $2,500,000 for the second
quarter of fiscal 2004.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including , but not limited to, certain delays
beyond the Company's control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products and
other risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission.

THERMOGENESIS CORP. Chapman is an internationally published scientist in the field of
blood systems development and pathogen inactivation of blood components and
has obtained 24 issued U.
Dr.

embryos cryolife

cryosurgery readable

ThermoGenesis Corp. Announces Second Quarter Results

(Nasdaq: KOOL) today announced results for its second quarter of fiscal
2005. and giving the conference name
"THERMOGENESIS".S.

sperm tissues

, THERMOGENESIS
CORP.
-- To upgrade and expand our engineering capabilities by the addition of
our new Vice President of R+D and expansion of our engineering and scientific
staff to assure that ongoing product development efforts of DAC, Thrombin
Processing Device ("TPD") and other projects to meet our 3-Year Business Plan
milestones. We are pleased with the results of these investments and look
forward to the acceptance of these products in their respective markets. Vice President of Research and
Development (R+D) at V."

About THERMOGENESIS CORP .

kuopio readable

03 per basic and diluted common share for the
second quarter of fiscal 2004.D.

microtubules kuopio

The increased operating expenses for the six months ended December 31,
2004 were used for the following:

-- To employ an outside Design and Development Engineering firm to
accelerate the development of the ("Divide and Capture") DAC Blood Separation
System.03) ($0. The Company's technology platforms lead the world in their
ability to produce biological products from single units of blood .

mazur readable

S.
has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992. Dr. The Company has been a leading supplier of
state-of -the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals
and blood banks since 1992.

readable cryosurgery

-- To increase our Phase III CryoSeal FS System clinical sites to eight in
an effort to complete our 150 patient enrollment by April 30, 2005.

nunc immortality

The net revenues for the six months ended December 31, 2004 were
$5,351,000 as compared to $4,643,000 for the six months ended December 31,
2003 , an increase of 15%. The call can be accessed by dialing: 800-860-2442 within the
U.Technologies (Vitex).
Prior to joining Vitex, he had 16 years of experience working for Baxter
Healthcare in the divisions of Applied Sciences and Transfusion Therapies
(Fenwal) including two years as an expatriate in Brussels, Belgium.

bioresearch cryopreservation

The TPD is a stand-alone disposable which is designed to produce 8.06)

Shares used in
computing per share
data 45,100,050 40,265,493 45,011,948 39,862,971

THERMOGENESIS CORP.

cryolife ova

Chapman commented, "I am very excited to have the opportunity of
joining the ThermoGenesis team and look forward to effectively contributing to
the development, launch and promotion of its life saving medical device
products for stem cell therapy and surgical hemostasis. Umbilical
cord blood banks are utilizing the Company's BioArchive(R) System as a
critical enabling technology for cryopreserving and archiving of cord blood
stem cells for transplant, while the AXP is an innovative cell purification
product which is designed to semi-automate the separation of cord blood into
its therapeutic form for freezing in the BioArchive.

microtubules sperm

Dr.

Cryobiology is the study of extremely cold temperatures on biological systems, from whole animals and plants to organs and individual cells.

immortality mazur

S. and entering the following account number: 459#
and the following passcode: 364495.

About ThermoGenesis Corp.08) ($0.
Condensed Balance Sheets
(Unaudited)

December 31, June 30,
2004 2004
ASSETS
Current assets:
Cash, cash equivalents and short
term investments $13,022,000 $16,612,000
Accounts receivable, net 2,598,000 3,107,000
Inventories 3,035,000 2,470,000
Other current assets 617,000 582,000

Total current assets 19,272,000 22,771,000

Equipment, net 1,241,000 1,146,000

Other assets 149,000 197,000

$20,662,000 $24,114,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable $1,158,000 $1,709,000
Other current liabilities 1,053,000 1,264,000

Total current liabilities 2,211,000 2,973,000

Long-term obligations and note
payable 103,000 173,000

Stockholders' equity 18,348 ,000 20,968,000

$20,662,000 $24,114 ,000

Chapman brings a wealth of
scientific knowledge and blood experience to the ThermoGenesis team. We are fortunate
to have John join our management team and look forward to benefiting from his
scientific expertise and his seasoned leadership in blood product
development.

kuopio cryobiology

06 per basic and diluted share for the six months
ended December 31, 2003.
-- Legal fees related to contract negotiations on pending strategic
distribution agreements and patent filings and issues. or 412-858 -4600 outside the U.
ThermoGenesis Corp. RANCHO CORDOVA, Calif.S. At Vitex, he successfully
authored a Phase I/II SBIR fast track grant totaling $1 million for
development of a blood purification system and led the multidisciplinary R+D
team from drug discovery to Phase III clinical trials. The CryoSeal(R) FS System
is used to prepare hemostatic and adhesive surgical sealants from the
patient 's blood in about an hour.

umbilical vial

The gross margin for the second quarter increased 18%
to $950,000 or 32 % of net revenues compared to $802,000 or 32% of net revenues
for the quarter ended December 31, 2003 .
-- To employ marketing studies of the distribution opportunities for the
DAC technology outside of cord blood stem cells. The TPD is not available in the United States. Umbilical
cord blood banks are utilizing the Company's BioArchive System as a critical
enabling technology for cryogenic archiving of stem cells for transplant,
while its CryoSeal(R) FS System is used to prepare hemostatic and adhesive
surgical sealants from patient blood in about an hour. It is stimulating to
join a company with product platforms that are both medically and commercially
significant and position the company for strong growth in the near term.

cryosurgery nanolithography

The net loss for the quarter ended
December 31, 2004, was $1,841 ,000 or $0. or
412-317-0088 outside the U.S. is a leader in enabling technologies for cell
therapeutics .

ova immortality

cryosurgery vial

We are now concluding the internal validation and beginning alpha
tests and preparing manufacturing units for beta launch in the fourth quarter."
The DAC System semi-automates the separation of whole blood into
components. Participants are asked to call the assigned number
approximately 5 minutes before the conference call begins. is a leader in enabling technologies for cell
therapeutics .

cryopreservation nanolithography